Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
Κύριοι συγγραφείς: | Leber, W, Lammel, O, Panovska-Griffiths, J, Czypionka, T |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Elsevier
2021
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
ανά: Yuming Sun, κ.ά.
Έκδοση: (2023-08-01) -
Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
ανά: Vinicius Fontanesi Blum, MD, MSc, κ.ά.
Έκδοση: (2021-11-01) -
Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
ανά: Zhiwen Fu, κ.ά.
Έκδοση: (2023-04-01) -
Impact of national-scale targeted point-of-care symptomatic lateral flow testing on trends in COVID-19 infections and hospitalisations during the second epidemic wave in Austria
ανά: Reitzinger, S, κ.ά.
Έκδοση: (2023) -
Impact of national-scale targeted point-of-care symptomatic lateral flow testing on trends in COVID-19 infections, hospitalisations and deaths during the second epidemic wave in Austria (REAP3)
ανά: Stephanie Reitzinger, κ.ά.
Έκδοση: (2023-03-01)